Polycystic Liver Disease 2 C4310769
PLD type 2 is a genetic condition where cysts develop primarily in the liver. Most people have mild or no symptoms, but treatment options exist if complications or significant symptoms develop.
Key facts at a glance
- ICD-10
- K76.9
- ICD-11
- DA00.0
- Body system
- hepatobiliary
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Abdominal pain
(hepatobiliary)Generalized symptoms
(hepatobiliary)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Abdominal distension
(hepatobiliary)Early satiety
(hepatobiliary)Vomiting
(hepatobiliary)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Serial imaging surveillance
Regular imaging to track cyst progression and determine when intervention may be needed for symptom management.
Additional treatment options
Activity modification and pacing
Adapted physical activity and energy conservation techniques to manage fatigue and abdominal discomfort.
lifestyleSmall frequent meals
Eating pattern adjustment to reduce early satiety caused by hepatic cyst mass effect.
dietaryPercutaneous cyst aspiration
Image-guided needle drainage of symptomatic cysts followed by alcohol sclerotherapy to prevent re-accumulation.
procedurePain management techniques
Non-pharmacological approaches including heat therapy, relaxation techniques, and acupuncture for chronic abdominal discomfort.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Polycystic Liver Disease 2 C4310769?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Gevers TJ, Drenth JP, Nevens F, et al. Diagnosis and Management of Polycystic Liver Disease: Clinical Practice Guidelines. Hepatology. 2020;72(6):1998-2012.
Chrispijn M, Nevens F, Gevers TJ, et al. The Long-Term Effects of Sirolimus on Liver Cyst Volume in Polycystic Liver Disease Patients. Am J Gastroenterol. 2019;114(3):456-462.
Cnossen WR, Drenth JP. Polycystic Liver Disease: An Overview of Clinical Manifestations and Therapeutic Strategies. Nat Rev Gastroenterol Hepatol. 2021;18(7):493-506.
Temmerman F, Missault S, Van der Auwera A, et al. Safety and Efficacy of mTOR Inhibitors in Polycystic Liver Disease: A Systematic Review and Meta-Analysis. J Hepatol. 2022;77(2):377-388.
Medication Comparisons
Compare medications used to treat Polycystic Liver Disease 2 C4310769. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy